Big Risks From Quick Drug Trials (Australia)
This article was originally published in PharmAsia News
Australian clinical drug trials must be approved by an ethics committee, which was formed in 1991 in an attempt to speed up the drug research and development process. Before that, all trials had to be approved by the Therapeutic Goods Administration. The committee has dramatically cut approval time from three years to three months. The quick approval process allowed over 3,000 clinical sites to be registered for trials last year. The Australian drug industry invests about $520 million a year on research and development. Approximately 90 percent of that money goes to clinical trials. In addition, many large U.S.-based pharmaceutical companies have also been attracted to the Australian R&D market. But critics worry the system may be too lax. Although there have been no major problems in Australia, health and safety regulations have been under increased scrutiny around the globe. Last year six healthy volunteers in England died during a drug trial, highlighting the risks of a clinical trial system that is largely self-regulating. (Click here for more
You may also be interested in...
HBW Insight speaks to new Global Self-Care Federation chair and Bayer CH chief Heiko Schipper about the role that self-care can play in alleviating pressure on national health care systems, the importance of self-care's scientific credentials and of maintaining supply chain continuity during the coronavirus pandemic.
AstraZeneca's research head admits that half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.
Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.